title: Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.
authors: Claudia
authors: C
authors: Stöllberger
authors: Stanislaus
authors: S
authors: Rakusan
authors: Florian T
authors: FT
authors: Wimpissinger
authors: Josef
authors: J
authors: Finsterer
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000556:secondary; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control*; D015897:Comorbidity; D000069604:Dabigatran; D006417:Hematuria / Q000139:chemically induced*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications; D055502:Secondary Prevention; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology; D016055:Urinary Retention / Q000139:chemically induced; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D016729:Leuprolide; D000069604:Dabigatran